Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2
Guoli Shi, … , Jacob S. Yount, Alex A. Compton
Guoli Shi, … , Jacob S. Yount, Alex A. Compton
Published October 20, 2022
Citation Information: J Clin Invest. 2022;132(24):e160766. https://doi.org/10.1172/JCI160766.
View: Text | PDF
Research Article Article has an altmetric score of 11

Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2

  • Text
  • PDF
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in immunocompromised individuals is associated with prolonged virus shedding and evolution of viral variants. Rapamycin and its analogs (rapalogs, including everolimus, temsirolimus, and ridaforolimus) are FDA approved as mTOR inhibitors for the treatment of human diseases, including cancer and autoimmunity. Rapalog use is commonly associated with an increased susceptibility to infection, which has been traditionally explained by impaired adaptive immunity. Here, we show that exposure to rapalogs increased susceptibility to SARS-CoV-2 infection in tissue culture and in immunologically naive rodents by antagonizing the cell-intrinsic immune response. We identified 1 rapalog (ridaforolimus) that was less potent in this regard and demonstrated that rapalogs promote spike-mediated entry into cells, by triggering the degradation of the antiviral proteins IFITM2 and IFITM3 via an endolysosomal remodeling program called microautophagy. Rapalogs that increased virus entry inhibited mTOR-mediated phosphorylation of the transcription factor TFEB, which facilitated its nuclear translocation and triggered microautophagy. In rodent models of infection, injection of rapamycin prior to and after virus exposure resulted in elevated SARS-CoV-2 replication and exacerbated viral disease, while ridaforolimus had milder effects. Overall, our findings indicate that preexisting use of certain rapalogs may elevate host susceptibility to SARS-CoV-2 infection and disease by activating lysosome-mediated suppression of intrinsic immunity.

Authors

Guoli Shi, Abhilash I. Chiramel, Tiansheng Li, Kin Kui Lai, Adam D. Kenney, Ashley Zani, Adrian C. Eddy, Saliha Majdoul, Lizhi Zhang, Tirhas Dempsey, Paul A. Beare, Swagata Kar, Jonathan W. Yewdell, Sonja M. Best, Jacob S. Yount, Alex A. Compton

×

Figure 2

Rapalogs promote SARS-CoV-2 infection in lung epithelial cells to different extents by counteracting the intrinsic antiviral state.

Options: View larger image (or click on image) Download as PowerPoint
Rapalogs promote SARS-CoV-2 infection in lung epithelial cells to differ...
(A) A549-ACE2 cells were treated with or without type I IFN (250 U/mL) for 18 hours and then with 20 μM rapamycin (Rap), everolimus (Eve), temsirolimus (Tem), ridaforolimus (Rid), or an equivalent volume of DMSO (D) for 4 hours. HIV-CoV-2 (100 ng p24 equivalent) was added to cells, and infection was measured by luciferase activity 48 hours after infection. Luciferase units were normalized to 100 in the DMSO condition in the absence of IFN. (B) A549-ACE2 cells from A were subjected to SDS-PAGE and Western blot analysis. Immunoblotting was performed with anti–IFITM2/-3, anti-ACE2, and anti-actin (in that order) on the same nitrocellulose membrane. The numbers and tick marks indicate the size (kDa) and position of protein standards in ladders. (C) Primary hSAECs were treated with 20 μM rapamycin, everolimus, temsirolimus, ridaforolimus, or an equivalent volume of DMSO for 4 hours. VSV-CoV-2 (50 μL) was added to cells, and infection was measured by GFP expression 24 hours after infection using flow cytometry. (D) A549-ACE2 cells were treated with varying concentrations of everolimus or DMSO (equivalent to 30 μM everolimus) for 4 hours. SARS-CoV-2 (nCoV-WA1-2020; MN985325.1) was added to the cells at an MOI of 0.1, and infectious titers were measured in VeroE6 cells by calculating the TCID50 per milliliter of supernatants recovered 24 hours after infection. TCID50 (PFU/mL) values are shown. Means and the standard error were calculated from 3–4 experiments. *P < 0.05 and **P < 0.01, by 1-way ANOVA versus DMSO.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 22 X users
On 1 Facebook pages
51 readers on Mendeley
See more details